Cost-effectiveness results
| QALYs | Total cost ($) | ICER ($/QALY) | |
| Sorafenib | 0.66 | 15 011.73 | / |
| HAIC-FO | 1.00 | 18 470.98 | 10 235.56 |
HAIC-FO, hepatic artery infusion chemotherapy of fluorouracil, leucovorin and oxaliplatin; ICER, incremental cost-effectiveness ratio; QALYs, quality-adjusted life years.